Echosens is Introducing FibroScan 630 Expert, an Innovative Device for Non-invasive Liver Diagnosis

PR73009

PARIS, April 11, 2018 /PRNewswire=KYODO JBN/ --

     Echosens, the company behind the industry-leading FibroScan technology, is

introducing FibroScan 630 Expert, a unique device that drives non-invasive

liver disease management to the next level.

(Photo:

https://mma.prnewswire.com/media/664142/Echosens_FibroScan_630_Expert.jpg     )

(Logo: https://mma.prnewswire.com/media/664145/Echosens_Logo.jpg )

    Chronic liver disease represents a major and rising public healthcare

issue, affecting more than one billion people worldwide. It can be caused by a

virus, such as hepatitis B or C, by excessive alcohol consumption or by dietary

habits, resulting in conditions such as Non-Alcoholic Fatty Liver Disease

(NAFLD) and Non-Alcoholic Steatohepatitis (NASH). These diseases generally

remain symptomless and undetected until their very late stages but they

progressively worsen over time and might ultimately lead to life-threatening

complications, such as liver cirrhosis and liver cancer.

    FibroScan is an accurate and efficient solution that quantifies liver

fibrosis and steatosis non-invasively in just a few minutes bringing extra

clinical confidence to support the management of patients with chronic liver

diseases, thus avoiding painful liver biopsies. FibroScan relies on proprietary

technology "Vibration-Controlled Transient Elastography", or VCTE, which relies

on the combination of shear waves and ultrasound generated at the tip of the

device's probe.

    The new flagship FibroScan enhances the exam's efficiency, extends the

patient's applicability and expands clinical capabilities.

    FibroScan 630 Expert features a high performance elastography engine,

improved ergonomics, embedded ultrasound guidance system, spleen-dedicated

exam, intuitive user interface, touchscreen and advanced keyboard, as well as

an integrated barcode reader.

    The new device will be launched at the International Liver Congress 2018

that takes place from April 11 to April 15, 2018 in Paris.

    About Echosens

    Echosens is an innovative high-technology company based in France. Since

its inception in 2001, Echosens has been recognized as the world's leading

provider of non-invasive diagnostic devices for patients with chronic liver

diseases. Innovative non-invasive technologies by Echosens are recognized for

cost effectively diagnosing and monitoring chronic liver diseases with

precision, standardization and repeatability over time and users. The Group

develops, manufactures and sells under its own names and trademarks duly

registered portfolio of products and solutions to physicians for the diagnosis,

assessment and monitoring of various chronic liver diseases. Liver diseases,

being a major rising public health issue, represent a main development focus

for Echosens.

    Contact:     

    Echosens     

    communication@echosens.com     

    +33-1-44-82-78-50

SOURCE: Echosens